Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 31 Records) |
| Query Trace: Neoplasms and FCGR3A[original query] |
|---|
| Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. European journal of cancer (Oxford, England : 1990) 2010 Jul 46 (10): 1829-34. Pander Jan, Gelderblom Hans, Antonini Ninja F, Tol Jolien, van Krieken Johan H J M, van der Straaten Tahar, Punt Cornelis J A, Guchelaar Henk-J |
| Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study). Anticancer research 2010 Oct 30 (10): 4209-17. Zhang Wu, Azuma Mizutomo, Lurje Georg, Gordon Michael A, Yang Dongyun, Pohl Alexandra, Ning Yan, Bohanes Pierre, Gerger Armin, Winder Thomas, Hollywood Ellen, Danenberg Kathleen D, Saltz Leonard, Lenz Heinz-Jos |
| Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer. BMC cancer 2011 Nov 11 (1): 1. Dahan L, Norguet E, Etienne-Grimaldi MC, Formento JL, Gasmi M, Nanni I, Gaudart J, Garcia S, Ouafik L, Seitz JF, Milano G |
| ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy. Oncology 2012 83 (4): 218-27. Kim Ji-Won, Kim Jee Hyun, Im Seock-Ah, Kim Yu Jung, Han Hye-Suk, Kim Jin-Soo, Han Sae-Won, Jeon Yoon Kyung, Oh Do-Youn, Han Wonshik, Kim Tae-You, Park In Ae, Noh Dong-Young, Bang Yung-J |
| Analysis of Fc? receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research 2012 Jun 18 (12): 3478-86. Hurvitz Sara A, Betting David J, Stern Howard M, Quinaux Emmanuel, Stinson Jeremy, Seshagiri Somasekar, Zhao Ying, Buyse Marc, Mackey John, Driga Adrian, Damaraju Sambasivarao, Sliwkowski Mark X, Robert Nicholas J, Valero Vicente, Crown John, Falkson Carla, Brufsky Adam, Pienkowski Tadeusz, Eiermann Wolfgang, Martin Miguel, Bee Valerie, Marathe Omkar, Slamon Dennis J, Timmerman John |
| Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan. British journal of clinical pharmacology 2012 May 73 (5): 776-85. Etienne-Grimaldi Marie-Christine, Bennouna Jaafar, Formento Jean-Louis, Douillard Jean-Yves, Francoual Mireille, Hennebelle Isabelle, Chatelut Etienne, Francois Eric, Faroux Roger, El Hannani Chaza, Jacob Jacques-Henri, Milano Géra |
| Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial. Breast cancer research and treatment 2013 Jun 139 (3): 789-800. Roca Lise, Diéras Véronique, Roché Henri, Lappartient Emmanuelle, Kerbrat Pierre, Cany Laurent, Chieze Stéphanie, Canon Jean-Luc, Spielmann Marc, Penault-Llorca Frédérique, Martin Anne-Laure, Mesleard Christel, Lemonnier Jérôme, de Cremoux Patric |
| A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2013 Jan . Paz-Ares L, Bálint B, de Boer RH, van Meerbeeck JP, Wierzbicki R, De Souza P, Galimi F, Haddad V, Sabin T, Hei YJ, Pan Y, Cottrell S, Hsu CP, Ramlau R |
| Association studies of Fc? receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831. Cancer immunology research 2014 Oct 2 (10): 962-9. Norton Nadine, Olson Rebecca M, Pegram Mark, Tenner Kathleen, Ballman Karla V, Clynes Raphael, Knutson Keith L, Perez Edith |
| FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. Gut 2015 Jun 64 (6): 921-8. Geva Ravit, Vecchione Loredana, Kalogeras Konstantinos T, Jensen Benny Vittrup, Lenz Heinz-Josef, Yoshino Takayuki, Paez David, Montagut Clara, Souglakos John, Cappuzzo Federico, Cervantes Andrés, Frattini Milo, Fountzilas George, Johansen Julia S, Høgdall Estrid Vilma, Zhang Wu, Yang Dongyun, Yamazaki Kentaro, Nishina Tomohiro, Papamichael Demetris, Vincenzi Bruno, Macarulla Teresa, Loupakis Fotios, De Schutter Jef, Spindler Karen Lise Garm, Pfeiffer Per, Ciardiello Fortunato, Piessevaux Hubert, Tejpar Sabi |
| FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab. BMC cancer 2014 14 (1): 340. Kjersem Janne B, Skovlund Eva, Ikdahl Tone, Guren Tormod, Kersten Christian, Dalsgaard Astrid M, Yilmaz Mette K, Fokstuen Tone, Tveit Kjell M, Kure Elin |
| FCGR2A, FCGR3A polymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer. Oncotarget 2015 Aug . Ying Hou-Qun, Wang Feng, Chen Xiao-Lin, He Bang-Shun, Pan Yu-Qin, Jie Chen, Liu Xian, Cao Wei-Jun, Peng Hong-Xin, Lin Kang, Wang Shu-K |
| Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Oct . Kenkre Vaishalee, Hong Fangxin, Cerhan James R, Lewis Marcia, Sullivan Leslie, Williams Michael E, Gascoyne Randy D, Horning Sandra J, Kahl Br |
| FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value? World journal of oncology 2015 Oct 6 (5): 437-440. Botticelli Andrea, Mazzuca Federica, Borro Marina, Mazzotti Eva, La Torre Marco, Bonifacino Adriana, Ciabatta Francesca Romana, Gentile Giovanna, Maddalena Chiara, Simmaco Maurizio, Marchetti Pao |
| Fc-? Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2016 May 22 (10): 2435-44. Liu Geoffrey, Tu Dongsheng, Lewis Marcia, Cheng Dangxiao, Sullivan Leslie A, Chen Zhuo, Morgen Eric, Simes John, Price Timothy J, Tebbutt Niall C, Shapiro Jeremy D, Jeffery G Mark, Mellor J Daniel, Mikeska Thomas, Virk Shakeel, Shepherd Lois E, Jonker Derek J, O'Callaghan Christopher J, Zalcberg John R, Karapetis Christos S, Dobrovic Alexand |
| Evaluation of antibody-dependent cell-mediated cytotoxicity activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients. World journal of gastrointestinal oncology 2016 Feb 8 (2): 222-30. Lo Nigro Cristiana, Ricci Vincenzo, Vivenza Daniela, Monteverde Martino, Strola Giuliana, Lucio Francesco, Tonissi Federica, Miraglio Emanuela, Granetto Cristina, Fortunato Mirella, Merlano Marco Car |
| Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial. JAMA oncology 2017 Mar 3 (3): 335-341. Gavin Patrick G, Song Nan, Kim S Rim, Lipchik Corey, Johnson Nicole L, Bandos Hanna, Finnigan Melanie, Rastogi Priya, Fehrenbacher Louis, Mamounas Eleftherios P, Swain Sandra M, Wickerham D Lawrence, Geyer Charles E, Jeong Jong-Hyeon, Costantino Joseph P, Wolmark Norman, Paik Soonmyung, Pogue-Geile Kay |
| Germline polymorphisms as biomarkers of tumor response in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a systematic review and meta-analysis. The pharmacogenomics journal 2016 Nov . Morgen E K, Lenz H-J, Jonker D J, Tu D, Milano G, Graziano F, Zalcberg J, Karapetis C S, Dobrovic A, O'Callaghan C J, Liu |
| FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Oct . Erbe Amy K, Wang Wei, Goldberg Jacob, Gallenberger Mikayla, Kim KyungMann, Carmichael Lakeesha, Hess Dustin, Mendonca Eneida A, Song Yiqiang, Hank Jacquelyn A, Cheng Su-Chun, Signoretti Sabina, Atkins Michael, Carlson Alexander, Mier James W, Panka David J, McDermott David F, Sondel Paul |
| The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab. The pharmacogenomics journal 2017 Jul . Magnes T, Melchardt T, Hufnagl C, Weiss L, Mittermair C, Neureiter D, Klieser E, Rinnerthaler G, Roesch S, Gaggl A, Greil R, Egle |
| FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125. Cytogenetic and genome research 2017 152 (4): 169-179. Wang Wenquan, Somers Elizabeth B, Ross Erin N, Kline J Bradford, O'Shannessy Daniel J, Schweizer Charles, Weil Susan, Grasso Luigi, Nicolaides Nicholas |
| Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the EGFR-inhibitor zalutumumab: results from the DAHANCA 19 trial. Acta oncologica (Stockholm, Sweden) 2018 May 1-6. Brøndum Line, Alsner Jan, Sørensen Brita Singers, Maare Christian, Johansen Jørgen, Primdahl Hanne, Evensen Jan Folkvard, Kristensen Claus Andrup, Andersen Lisbeth Juhler, Overgaard Jens, Eriksen Jesper Gr |
| Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. Cancer medicine 2018 Oct . Shepshelovich Daniel, Townsend Amanda R, Espin-Garcia Osvaldo, Latifovic Lidija, O'Callaghan Chris J, Jonker Derek J, Tu Dongsheng, Chen Eric, Morgen Eric, Price Timothy J, Shapiro Jeremy, Siu Lillian L, Kubo Michiaki, Dobrovic Alexander, Ratain Mark J, Xu Wei, Mushiroda Taisei, Liu Geoffr |
| Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity. JACC. Heart failure 2019 8 7 (9): 795-804. Goel Shom, Liu Jia, Guo Hao, Barry William, Bell Richard, Murray Bronwyn, Lynch Jodi, Bastick Patricia, Chantrill Lorraine, Kiely Belinda E, Abdi Ehtesham, Rutovitz Josie, Asghari Ray, Sullivan Anne, Harrison Michelle, Kohonen-Corish Maija, Beith Ja |
| Impact of Human Fc?R Gene Polymorphisms on IgG-Triggered Cytokine Release: Critical Importance of Cell Assay Format. Frontiers in immunology 2019 10 390. Hussain Khiyam, Hargreaves Chantal E, Rowley Tania F, Sopp Joshua M, Latham Kate V, Bhatta Pallavi, Sherington John, Cutler Rona M, Humphreys David P, Glennie Martin J, Strefford Jonathan C, Cragg Mark |
| NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2 breast cancer. Breast cancer research : BCR 2019 Dec 21 (1): 133. Jacobs Samuel A, Robidoux André, Abraham Jame, Pérez-Garcia José Manuel, La Verde Nicla, Orcutt James M, Cazzaniga Marina E, Piette Fanny, Antolín Silvia, Aguirre Elena, Cortes Javier, Llombart-Cussac Antonio, Di Cosimo Serena, Kim Rim S, Feng Huichen, Lipchik Corey, Lucas Peter C, Srinivasan Ashok, Wang Ying, Song Nan, Gavin Patrick G, Balousek April D, Paik Soonmyung, Allegra Carmen J, Wolmark Norman, Pogue-Geile Katherine |
| Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab. The pharmacogenomics journal 2019 1 20 (2): 350. Magnes T, Melchardt T, Hufnagl C, Weiss L, Mittermair C, Neureiter D, Klieser E, Rinnerthaler G, Roesch S, Gaggl A, Greil R, Egle |
| Anti-CD20 rituximab IgG1, IgG3, and IgG4 but not IgG2 subclass trigger Ca mobilization and cytotoxicity in human NK cells. Journal of leukocyte biology 2020 Jul . Freitas Monteiro Marta, Papaserafeim Maria, Réal Aline, Puga Yung Gisella L, Seebach Jörg |
| Identification of genetic variations associated with drug resistance in non-small cell lung cancer patients undergoing systemic treatment. Briefings in bioinformatics 2021 5 22 (6): . Luo Ruihan, Ge Chuang, Xiao Xiao, Song Jing, Miao Shiqi, Tang Yongyao, Lai Jiayi, Nian Weiqi, Song Fangzhou, Ran Long |
| [Bioinformatic analysis of the relationship between protein phosphatase 2A catalytic subunit alpha (PPP2CA) expression and prognosis and immune infiltration in colorectal cancer patients]. Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology 2024 8 40 (7): 591-604. Xiaojie Liang, Zhaoxiang Cheng, Weiwei Shang, Xinhao Chen, Jun |
- Page last reviewed:Feb 1, 2024
- Content source: